FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
Project Oncology® - Un pódcast de ReachMD
Categorías:
Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer. Released on December 21, 2017
